AU9479301A - Viruses targeted to hypoxic cells and tissues - Google Patents

Viruses targeted to hypoxic cells and tissues

Info

Publication number
AU9479301A
AU9479301A AU9479301A AU9479301A AU9479301A AU 9479301 A AU9479301 A AU 9479301A AU 9479301 A AU9479301 A AU 9479301A AU 9479301 A AU9479301 A AU 9479301A AU 9479301 A AU9479301 A AU 9479301A
Authority
AU
Australia
Prior art keywords
tissues
hypoxia
genes
operably linked
hypoxic cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU9479301A
Other languages
English (en)
Inventor
Erwin Van Meir
Ainsley C Nicholson
Dawn E Post
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of AU9479301A publication Critical patent/AU9479301A/xx
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU9479301A 2000-09-26 2001-09-26 Viruses targeted to hypoxic cells and tissues Pending AU9479301A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23528300P 2000-09-26 2000-09-26
PCT/US2001/030236 WO2002026192A2 (en) 2000-09-26 2001-09-26 Viruses targeted to hypoxic cells and tissues

Publications (1)

Publication Number Publication Date
AU9479301A true AU9479301A (en) 2002-04-08

Family

ID=22884861

Family Applications (2)

Application Number Title Priority Date Filing Date
AU9479301A Pending AU9479301A (en) 2000-09-26 2001-09-26 Viruses targeted to hypoxic cells and tissues
AU2001294793A Ceased AU2001294793B2 (en) 2000-09-26 2001-09-26 Viruses targeted to hypoxic cells and tissues

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001294793A Ceased AU2001294793B2 (en) 2000-09-26 2001-09-26 Viruses targeted to hypoxic cells and tissues

Country Status (7)

Country Link
EP (1) EP1328291B1 (enExample)
JP (1) JP4709471B2 (enExample)
AT (1) ATE418342T1 (enExample)
AU (2) AU9479301A (enExample)
CA (1) CA2423833C (enExample)
DE (1) DE60137137D1 (enExample)
WO (1) WO2002026192A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2501010A1 (en) * 2002-10-01 2004-04-15 Duke University Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors
US20040142558A1 (en) 2002-12-05 2004-07-22 Granneman Ernst H. A. Apparatus and method for atomic layer deposition on substrates
US7601223B2 (en) 2003-04-29 2009-10-13 Asm International N.V. Showerhead assembly and ALD methods
US7537662B2 (en) 2003-04-29 2009-05-26 Asm International N.V. Method and apparatus for depositing thin films on a surface
US20080077999A1 (en) * 2004-03-23 2008-03-27 Eisai R&D Management Co., Ltd. Using Nonhuman Animal Model, Method of Measuring Transcription Activity Method of Measuring Cell Quantity and Method of Measuring Tumor Volume
US8487087B2 (en) 2005-03-11 2013-07-16 Oriental Yeast Co., Ltd. Model animal in which state of disease condition is observable in real time, gene construct for achieving the same and use of the same
CN108623693B (zh) * 2017-03-20 2022-03-25 徐寒梅 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用
CN116064675B (zh) * 2022-07-22 2024-12-03 西安电子科技大学 一种重组质粒、重组慢病毒载体、稳转细胞系及其构建方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783435A (en) * 1996-08-06 1998-07-21 Lamparski; Henry G. Prostate cancer drug screenings
CA2308575A1 (en) * 1997-11-03 1999-05-14 Tom Tsang Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
US6900049B2 (en) * 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof

Also Published As

Publication number Publication date
WO2002026192A3 (en) 2002-08-08
DE60137137D1 (de) 2009-02-05
EP1328291A4 (en) 2005-07-06
JP2004509635A (ja) 2004-04-02
EP1328291B1 (en) 2008-12-24
JP4709471B2 (ja) 2011-06-22
EP1328291A2 (en) 2003-07-23
ATE418342T1 (de) 2009-01-15
WO2002026192A2 (en) 2002-04-04
AU2001294793B2 (en) 2006-06-29
CA2423833A1 (en) 2002-04-04
CA2423833C (en) 2011-02-22

Similar Documents

Publication Publication Date Title
Mayeda et al. Two members of a conserved family of nuclear phosphoproteins are involved in pre-mRNA splicing.
WO1999011764A3 (en) Methods for generating high titer helper-free preparations of recombinant aav vectors
WO1998041629A3 (en) Death domain containing receptor 5
ATE366814T1 (de) Gl50 moleküle, sowie verwendungen derselben
KR20220061282A (ko) 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
MXPA02001878A (es) Moleculas b7-4 novedosas y usos de las mismas.
AU9479301A (en) Viruses targeted to hypoxic cells and tissues
TW200508246A (en) Anti-dengue virus antibodies, compositions, methods and uses
DK1144600T3 (da) Akt-3-nukleinsyre, polypeptider og anvendelser deraf
CA2449013A1 (en) Viral mutants that selectively replicate in targeted human cancer cells
WO2003008449A8 (en) Ntb-a, a surface molecule involved in natural killer cells activity
WO2002005843A3 (en) Human rrp sequences and methods of use
DE60237613D1 (de) Neue pgc-1-isoformen und deren verwendungen
US20090104154A1 (en) Composition and method for killing of tumours
O'Brien et al. Coexpression of the uracil phosphoribosyltransferase gene with a chimeric human nerve growth factor receptor/cytosine deaminase fusion gene, using a single retroviral vector, augments cytotoxicity of transduced human T cells exposed to 5-fluorocytosine
WO2001077293A3 (en) Gp40 and uses thereof
Smiben LeuSp DNA-binding domain-about turn!
Li et al. Synergistic antitumor efficacy of oncolytic adenovirus combined with chemotherapy
WO2024246427A1 (en) Fas ligand variant and recombinant cell having increased cytotoxicity and greater survival
WO2002044357A3 (en) Methods of using 18903 to treat pain and pain-related disorders
KR100732248B1 (ko) ＶＥＧＦ 안티센스 ｃＤＮＡ를 함유하는 재조합아데노-연관 바이러스（ｒＡＡＶ）및 이를 함유하는 대장암및/또는 폐암 특이적 유전자 치료제
WO2003087334A2 (en) Use of aav integration efficiency element for mediating site-specific integration of a transcription unit
ATE476194T1 (de) Ein mitglied der menschlichen proteinkinasefamilie, und verwendungen dafür
WO2002002743A3 (en) The nip3 family of proteins
AU2002359572A1 (en) 15603, a human ion channel family member